Spruce Biosciences, Inc. - Common Stock (SPRB)

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

Discover the stocks with unexpected trading volume in today's session on the US markets.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Spruce Biosciences discontinues tildacerfont trials for CAH as CAHmelia-204 misses primary endpoint and CAHptain-205 shows dose-dependent trends.

SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.

SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago.

Spruce Biosciences faces setbacks as tildacerfont trials fail primary endpoints, raising concerns about drug efficacy and compliance. Analysts downgrade ratings and adjust price targets amid uncertainty.

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.35% to 38,905.20 while the NASDAQ fell 0.13% to 16,156.28. The S&P 500 also fell, dropping, 0.25% to 5,152.46.

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.30% to 38,926.22 while the NASDAQ fell 0.44% to 16,107.04. The S&P 500 also fell, dropping, 0.39% to 5,145.38.

U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&P 500 also rose, gaining, 0.14% to 5,172.33.

Anheuser-Busch stock is falling on Thursday following news that 10% holder Altria is selling a portion of its stake in BUD shares.

Spruce Biosciences' latest CAH studies: CAHmelia-203 & CAHptain-205. Discover insights on tildacerfont's efficacy, safety, and pharmacokinetics in adult & pediatric CAH patients.